表紙
市場調查報告書
商品編碼
1068649

下一代診斷的前景(2022)

Next-generation Diagnostics Outlook, 2022

出版日期: | 出版商: Frost & Sullivan | 英文 49 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球下一代診斷市場是與 COVID-19 相關的緊急診斷的支柱,預計從 2020 年到 2021 年初,25% 至 30% 的收入將與該測試相關。隨著用於慢性病篩查的血液檢測和用於 COVID-19 相關檢測的下一代分子和即時診斷的出現,市場在 2021 年增長了 15.5%。

加快審批渠道有望促進未來幾年的快速發展。越來越多的家庭醫療保健工具包、對檢測和消耗品的需求激增、設備的小型化以及能夠在廣泛的環境中使用的工作流程自動化預計將成為增長的載體。

本報告對下一代診斷市場進行研究和分析,並提供有關戰略基本要求、增長機會分析、區域前景、案例研究以及市場增長促進和增長抑制因素趨勢的信息。

目錄

戰略要求

  • 為什麼增長變得更加困難
  • 戰略要務 8 (TM)
  • 三大戰略要求對下一代診斷的影響
  • 增長機會推動增長管道引擎 (TM)

分析亮點

  • 分析要點
  • 收入明細(2021 年)
  • 主要預測(2022 年)

成長環境

  • 市場細分
  • 成長環境

宏觀經濟因素

  • 全球 GDP 增長率
  • 全球 GDP 增長率快照(2022 年)
  • 供應鏈中斷的影響分析
  • 無障礙工作的影響分析

2022 年收入趨勢

  • 收入預測:按細分市場

2022年5大項目預測

  • 預測 1
  • 預測 2
  • 預測 3
  • 預測 4
  • 預測 5

2022 年細分市場展望

  • 臨床化學/免疫分析市場快照
  • 分子診斷市場快照
  • POCT 市場快照
  • 體外診斷精選公司

增長機會宇宙

  • 增長機會 1-液體活檢作為生物標誌物驅動的精準腫瘤學工具
  • 增長機會 2-分佈式/點護理分子檢測傳染病
  • 診斷實驗室數字化轉型的增長機會 3-SLaaS(智能實驗室即服務)

結論

  • 結論與未來展望

下一步

  • 下一步
  • 展品清單
  • 免責聲明
目錄
Product Code: K73A-55

Recovery in Routine Testing and Focus on Personalized Diagnostics to Propel Growth

In vitro diagnostics introduces new technologies, sequencing methods, novel software algorithms, and multi-omics approaches to realise the goal of personalized medicine. Next-generation diagnostics has been the backbone of COVID-19-related emergency diagnosis, with an estimated 25% to 30% of revenue during 2020 and early 2021 related to this testing.

With the arrival of blood-based assays for chronic disease screening and next-generation molecular and point-of-care diagnostics for COVID-19-related testing, the global market grew 15.5% in 2021. Digital health solutions (patient portal + mobile app) facilitate a dramatic shift in care delivery from traditional to alternative sites, simplifying accessibility of diagnostic tests, and delivering an automated testing experience for labs to ensure rapid scalability. Patients have greater access control/faster turnaround time to results; providers can triage patients quickly through an efficient and connected workflow.

An accelerated approval pathway would foster rapid development over the next few years. The increase in availability of home care kits, spike in demand for assays and consumables, compactness of devices, and automation of workflows to serve a broad spectrum of settings are growth vectors. Early detection to initiate optimal treatment plans is a paradigm shift in personalized care.

The outlook report forecasts revenue for molecular diagnostics, point-of-care testing, clinical chemistry and immunoassays. It considers strategic imperatives, macroeconomic trends, and growth opportunities, and presents 5 predictions for 2022.

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top Three Strategic Imperatives on Next-generation Diagnostics
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Analysis Highlights

  • Analysis Highlights
  • 2021 Revenue Breakdown
  • Top Predictions for 2022

Growth Environment

  • Market Segmentation
  • Growth Environment

Macroeconomic Factors

  • Global GDP Growth
  • 2022 Global GDP Growth Snapshot
  • Supply Chain Disruptions Impact Analysis
  • Accessibility Initiatives Impact Analysis

Revenue Trends, 2022

  • Revenue Forecast by Segment
  • Revenue Forecast by Segment (continued)

Top 5 Predictions, 2022

  • Prediction 1
  • Prediction 2
  • Prediction 3
  • Prediction 4
  • Prediction 5

Segment Outlook, 2022

  • Clinical Chemistry and Immunoassays Market Snapshot
  • Molecular Diagnostics Market Snapshot
  • POCT Market Snapshot
  • In Vitro Diagnostics Companies to Watch

Growth Opportunity Universe

  • Growth Opportunity 1-Liquid Biopsy as a Biomarker-driven Tool for Precision Oncology
  • Growth Opportunity 1-Liquid Biopsy as a Biomarker-driven Tool for Precision Oncology (continued)
  • Growth Opportunity 2-Decentralized and Point-of-Care Molecular Testing for Infectious Disease
  • Growth Opportunity 2-Decentralized and Point-of-Care Molecular Testing for Infectious Disease (continued)
  • Growth Opportunity 3-Smart Labs as a Service for the Digital Transformation of Diagnostic Laboratories
  • Growth Opportunity 3-Smart Labs as a Service for the Digital Transformation of Diagnostic Laboratories (continued)

Conclusions

  • Conclusions and Future Outlook

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • Legal Disclaimer